BRTX

Insider Trades

Name	Value	Action	Price	Current Price
Broadrick Dale10 Percent Owner $1.8k1.1k shares SellOct 28, 2024 $1.58 --

News

globenewswire.comBioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growthglobenewswire.comJun 18

prnewswire.comKaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)prnewswire.comMay 27

globenewswire.comBioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Dataglobenewswire.comMay 26

zacks.comWhat Makes Biorestorative Therapies (BRTX) a New Buy Stockzacks.comMay 15

Trade BRTX

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.

CEO: Lance Alstodt
IPO Date: Dec 5, 2012

Market Data

Open: $0.37
High: $0.4099
Low: $0.37
Volume: 584.2K
Avg Volume: 11M
52W High: $1.89
52W Low: $0.1593

Valuation

Market Cap: $3.7M
Enterprise Value: $605k
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-11M
Revenue: $360k
Net Income: $-14M
Cash: $1.5M
Debt: $0

Events

EarningsAug 11

EPS est. -0.15